Reply to Letter to the Editor: 'Anticoagulation in Real-Life Patients with Atrial Fibrillation: Impact of Renal Disease'.
作者信息
Güzel Tuncay, Aktan Adem, Kılıç Raif, Arslan Bayram, Demir Muhammed, Özbek Mehmet, Ertaş Faruk
机构信息
Department of Cardiology, Health Science University, Gazi Yaşargil Training and Research Hospital, Diyarbakır, Türkiye.
Department of Cardiology, Mardin Training and Research Hospital, Mardin, Türkiye.
出版信息
Anatol J Cardiol. 2023 Jan;27(1):56-58. doi: 10.14744/AnatolJCardiol.2022.2335.
Abstract
摘要
相似文献
1
Reply to Letter to the Editor: 'Anticoagulation in Real-Life Patients with Atrial Fibrillation: Impact of Renal Disease'.致编辑信函的回复：“真实世界中房颤患者的抗凝治疗：肾脏疾病的影响”
Anatol J Cardiol. 2023 Jan;27(1):56-58. doi: 10.14744/AnatolJCardiol.2022.2335.
2
Reply to the letter to the editor regarding "Nonvalvular atrial fibrillation in patients undergoing chronic haemodialysis, should we anticoagulate?".
Nefrologia (Engl Ed). 2023 Jan-Feb;43(1):150-151. doi: 10.1016/j.nefroe.2023.03.014. Epub 2023 Apr 4.
3
'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.“真实世界”的心房颤动抗栓治疗：EORP-AF 初步调查。
Am J Med. 2014 Jun;127(6):519-29.e1. doi: 10.1016/j.amjmed.2013.12.022. Epub 2014 Jan 28.
4
Anticoagulation in Real-Life Patients with Atrial Fibrillation: Impact of Renal Disease.心房颤动真实患者的抗凝治疗：肾脏疾病的影响
Anatol J Cardiol. 2023 Jan;27(1):54-55. doi: 10.14744/AnatolJCardiol.2022.2333.
5
Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation.慢性肾脏病中的心房颤动：权衡抗凝治疗的风险与获益。
Am J Kidney Dis. 2013 Sep;62(3):615-32. doi: 10.1053/j.ajkd.2013.02.381. Epub 2013 Jun 5.
6
Anticoagulation in atrial fibrillation.心房颤动的抗凝治疗
Heart. 2021 Mar;107(5):419-427. doi: 10.1136/heartjnl-2020-316728. Epub 2020 Oct 28.
7
Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety.心房颤动合并慢性肾脏病患者的抗凝治疗：疗效与安全性。
Expert Opin Drug Saf. 2013 Jan;12(1):53-63. doi: 10.1517/14740338.2013.732569. Epub 2012 Oct 24.
8
Does the risk exceed the benefit for anticoagulation in end-stage renal disease patients with nonrheumatic atrial fibrillation?
Semin Dial. 2011 Jul-Aug;24(4):387-8. doi: 10.1111/j.1525-139X.2011.00885.x.
9
10
Assessing Eligibility for Anticoagulation After Diagnosis of Atrial Fibrillation--Reply.
JAMA. 2015 Sep 1;314(9):949-50. doi: 10.1001/jama.2015.8995.
本文引用的文献
1
Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study.土耳其 AFTER-2 研究：非瓣膜性心房颤动患者口服抗凝治疗与长期随访结果。
Anatol J Cardiol. 2022 Jul;26(7):567-576. doi: 10.5152/AnatolJCardiol.2022.1597.
2
Should We Continue Assessing Glomerular Filtration Rate with the Cockroft-Gault Formula in NOAC-Treated Patients? The Magnitude of the Problem.在接受新型口服抗凝药（NOAC）治疗的患者中，我们是否应该继续使用 Cockcroft-Gault 公式评估肾小球滤过率？问题的严重程度。
J Clin Med. 2020 Jun 17;9(6):1893. doi: 10.3390/jcm9061893.
3
Bleeding in anticoagulated patients with atrial fibrillation: practical considerations.抗凝治疗的心房颤动患者出血：实际考虑。
Kardiol Pol. 2020 Feb 25;78(2):105-116. doi: 10.33963/KP.15205. Epub 2020 Jan 14.
4
Trends in antithrombotic management of patients with atrial fibrillation. A report from the Polish part of the EURObservational Research Programme - Atrial Fibrillation General Long-Term Registry.心房颤动患者抗栓治疗趋势。EURObservational Research Programme - Atrial Fibrillation General Long-Term Registry 波兰部分的报告。
Pol Arch Intern Med. 2020 Mar 27;130(3):196-205. doi: 10.20452/pamw.15157. Epub 2020 Jan 24.
5
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.2019年美国心脏协会/美国心脏病学会/心律学会对2014年美国心脏协会/美国心脏病学会/心律学会心房颤动患者管理指南的聚焦更新：美国心脏病学会/美国心脏协会临床实践指南工作组和心律学会与胸外科医师协会合作报告
Circulation. 2019 Jul 9;140(2):e125-e151. doi: 10.1161/CIR.0000000000000665. Epub 2019 Jan 28.
6
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.抗栓治疗心房颤动：CHEST 指南和专家报告。
Chest. 2018 Nov;154(5):1121-1201. doi: 10.1016/j.chest.2018.07.040. Epub 2018 Aug 22.
7
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.2018 年欧洲心脏病学会关于非维生素 K 拮抗剂口服抗凝剂在心房颤动患者中应用的实用指南。
Eur Heart J. 2018 Apr 21;39(16):1330-1393. doi: 10.1093/eurheartj/ehy136.
8
9
ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study).评估非瓣膜性心房颤动中风预防策略的真实生活多中心调查（RAMSES研究）。
Anatol J Cardiol. 2016 Oct;16(10):734-741. doi: 10.14744/AnatolJCardiol.2016.6752.
10
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动管理指南。
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
Zotero 插件